London, UK, 22 July 2025: Vicebio Ltd (“Vicebio” or the “Company”),a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi. Under the terms of the agreement, subject to customary conditions, Vicebio shareholders will receive up to a total of US$1.6 billion, including an …

Read More